RE: Medimmune30 Oct 2018 21:53
Definately the appointment to lead the Nuvec project makes the outcome promising. "The Company is delighted to announce the appointment of Andrew Leishman as Head of Nuvec® Development. Having previously worked at Astra Zeneca as a Senior Research Scientist, Andrew brings with him a wealth of research and development expertise to the Company’s lead vaccine delivery program. Andrew has worked on a variety of clinical and pre-clinical assets across respiratory, inflammation and oncology for several pharmaceutical companies."